To infinity and beyond! The sufficiency requirements for open-ended ranges (T 1977/22)
The recent Board of Appeal decision in T 1977/22 related to the patentability of claims defining subject matter with open-ended...
top of page
Functional claims for pharmaceutical formulations: Validity versus enforcement (T 2130/22)
The Board of Appeal decision in T 2130/22 considered the inventive step of a pharmaceutical formulation in which the technical effect...
Falling between the cracks: The challenges of patent strategy for stem cell therapies (T 1259/22)
Cell therapy is a highly innovative therapeutic strategy that uses living cells to combat disease. Cell therapy strategies include stem...
The benefits and pitfalls of drug manufacturing IP (T 2543/22)
The Board of Appeal decision in T 2543/22 relates to a manufacturing method for preparing a therapeutic peptide. The Board of Appeal...
A new mode of administration is a new specific medical use (but not necessarily inventive) (T 0295/22)
The Board of Appeal decision in T 0295/22 tackles the question of whether a new mode of administration of a drug should be considered a...
EBA's preliminary opinion in G1/24: "the description and the figures can be referred to in the course of claim interpretation"
The Enlarged Board of Appeal (EBA) has issued its preliminary opinion in the closely watched referral G1/24 relating to the role of the...
bottom of page